
TargImmune successfully closed its 2021 financing round
27.07.2021
TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...
27.07.2021
TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...
29.06.2021
Monte Rosa Therapeutics, a US-Swiss biotech company focused on discovering and developing precision medicines that degrade disease-causing proteins, reached...
15.06.2021
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.
14.06.2021
The Technologiepark Basel and the Swiss Biotech Association invite you to a virtual talk about: ‘How to attract and retain best talents for Life Sciences startups’.